CD276 and neoplasm: The adoptive immunotherapy that utilizes effector lymphocytes expressing tumor-specific antibodies based on B7-H3 has been widely explored in different tumors, including chimeric antigen receptors (CARs) (52, 53) and bispecific killer cell engagers (BiKE) (27, 54).